CJC-1295 & Ipamorelin:
Synergistic Interaction Modeling.
Molecular Synergy
The combination of CJC-1295 (a Growth Hormone Releasing Hormone analog) and Ipamorelin (a selective Growth Hormone Secretagogue) is a primary focus in contemporary peptide research. This dual-pathway approach is studied for its ability to simulate natural physiological pulses through two distinct mechanisms: GHRH receptor activation and Ghrelin receptor mimicry.
CJC-1295 (No DAC vs DAC)
CJC-1295 is a 29-amino acid peptide that functions as a GHRH analog. The "DAC" (Drug Affinity Complex) version incorporates a maleimidopropionic acid group to extend the peptide's half-life by binding to plasma albumin. In laboratory modeling, the choice between DAC and No DAC depends on the required duration of receptor saturation.
Ipamorelin Selectivity
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) known for its high selectivity. Unlike earlier GHRPs, laboratory observations indicate that Ipamorelin does not significantly influence prolactin or cortisol levels, making it a "cleaner" secretagogue for precise physiological modeling.
Technical Bibliographic Context
Co-Lyophilization Tech
Our blend is co-lyophilized in a single vial to ensure precise molecular ratios and prevent sedimentation. This vacuum-sealing process maintains the structural integrity of both peptides simultaneously.
Stability Parameters
Research indicates that the CJC/IPA blend is most stable when stored in a light-shielded environment at temperatures below 4°C post-reconstitution. Avoid exposure to direct UV radiation.
Research Use Only Disclaimer
This compound is strictly intended for laboratory research and in-vitro modeling. It is not for human consumption, therapeutic use, or clinical application. All information provided is for educational and technical purposes only.
Technical Specifications
Sourcing CJC + IPA
Obtain high-precision CJC-1295 + Ipamorelin blends for your institutional research requirements in Australia.
Source Blend